AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is conducting a Phase 1 clinical study titled ‘A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)’. The study aims to evaluate the safety and tolerability of AZD9833, both as a standalone treatment and in combination with other drugs, for women with advanced breast cancer that is resistant to endocrine therapy.
The study is testing AZD9833, a drug intended to treat endocrine-resistant ER+ HER2- breast cancer. It is being evaluated alone and in combination with other drugs like palbociclib, everolimus, abemaciclib, capivasertib, ribociclib, and anastrozole, to determine the most effective and safe dosage.
This interventional study is randomized and follows a sequential intervention model, focusing on treatment. There is no masking involved, meaning all participants and researchers know which treatments are being administered.
The study began on October 11, 2018, with its primary completion and estimated completion dates not specified. The last update was submitted on July 8, 2025, indicating ongoing progress in the study.
This update could influence AstraZeneca’s stock performance positively if the results show promise, as it would strengthen their oncology portfolio. Competitors in the oncology space may also feel pressure to advance their own research initiatives.
The study is ongoing, with further details available on the ClinicalTrials portal.